このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Atai Life Sciences 配当金

配当金基準チェック /06

Atai Life Sciences配当金を支払った記録がありません。

主要情報

n/a

配当利回り

n/a

配当性向

業界平均利回り	2.2%
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
一株当たり利益	-US$0.20
3年後の配当利回り予想	0%

最近の配当金アップデート

更新なし

Recent updates

ATAI: Enormous Potential Upside But No Clarity Yet

May 27

Is Atai Life Sciences (NASDAQ:ATAI) Using Debt Sensibly?

Mar 02

atai Life Sciences achieves positive results in phase 1 trial of kratom-derived drug

Oct 12

決済の安定と成長

配当データの取得

安定した配当: ATAIの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: ATAIの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Atai Life Sciences 配当利回り対市場

ATAI 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (ATAI)	n/a
市場下位25% (US)	1.5%
市場トップ25% (US)	4.8%
業界平均 (Pharmaceuticals)	2.2%
3年後のアナリスト予想 (ATAI)	0%

注目すべき配当: ATAIは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: ATAIは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: ATAIの配当性向を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: ATAIが配当金を報告していないため、配当金の持続可能性を計算できません。

Atai Life Sciences 配当金

配当金 基準チェック /06

主要情報

最近の配当金アップデート

Recent updates

Atai Life Sciences Announces Update on Beckley Psytech’S Phase 1/2A Trial of Ele-101 (Iv Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2A

ATAI: Enormous Potential Upside But No Clarity Yet

Atai Life Sciences N.V. Announces Board and Supervisory Board Changes

Co-Founder recently sold US$291k worth of stock

First quarter 2024 earnings released: US$0.17 loss per share (vs US$0.21 loss in 1Q 2023)

Atai Life Sciences N.V. Announces CEO Changes

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

Atai Life Sciences N.V., Annual General Meeting, May 17, 2024

atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

Co-Founder & Chief Scientific Officer recently sold US$114k worth of stock

Price target decreased by 19% to US$11.80

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

Price target increased by 18% to US$14.50

atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01

Is Atai Life Sciences (NASDAQ:ATAI) Using Debt Sensibly?

atai Life Sciences Announces Management Changes

Atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)

Atai Life Sciences N.V. (NasdaqGM:ATAI) acquired remaining stake of DemeRx IB, Inc.

Atai Life Sciences N.V. (NasdaqGM:ATAI) acquired remaining stake of DemeRx IB, Inc.

Atai Life Sciences N.V. Announces Executive Changes

Atai Life Sciences N.V. Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants

Co-Founder & CEO recently bought US$58k worth of stock

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates decrease by 48%, EPS upgraded

atai Life Sciences Announces Results from the Phase 1 Iv-To-Subcutaneous Bridging Study of Pcn-101 (R-Ketamine)

Consensus revenue estimates increase by 19%

Co-founder & CEO recently bought US$104k worth of stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of Grx-917

Atai Life Sciences Announces Results from Phase 2A Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression

Price target decreased to US$20.97

598 Initiates Phase 2B Proof-Of-Concept Trial of Rl-007 for Cognitive Impairment Associated with Schizophrenia

Atai Life Sciences Appoints Sahil V. Kirpekar as Chief Business Officer

Atai Life Sciences N.V. and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment

Consensus forecasts updated

Consensus forecasts updated

Alexis De Rosnay Resigns as a Member of the Supervisory Board of Directors of Atai Life Sciences N.V

Atai Life Sciences N.V. to Report Q3, 2022 Results on Nov 10, 2022

Atai Life Sciences and Perception Neuroscience Completes Enrollment for Phase 2A Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression

Atai Life Sciences N.V. Announces Initiation of Phase 1 Proof-Of-Concept Clinical Trial for Its Sol-Gel Based Direct-To-Brain Drug Delivery Technology

Atai Life Sciences N.V. Appoints Stephen Bardin as Managing Director

Atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD

atai Life Sciences achieves positive results in phase 1 trial of kratom-derived drug

Atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and Iv Vls-01, A Synthetic Form of Dmt

Atai Life Sciences: Decentralized Drug Discovery Platform

atai Life Sciences N.V. Announces Initiation of Phase 1 Trial for Its MDMA Derivative, EMP-01

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.37 loss in 2Q 2021)

ATAI Life Sciences GAAP EPS of -$0.24 misses by $0.01

We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely

Atai Life Sciences N.V. to Report Q2, 2022 Results on Aug 15, 2022

Price target decreased to US$23.72

Atai Life Sciences: Leading But Early Stage Psychedelic Therapeutics Developer

atai Life Sciences company Kures Therapeutics appoints Dr. Chad Beyer as CEO

Atai Life Sciences N.V. Announces Executive Changes

Atai Life Sciences N.V.: A First Take

Atai Life Sciences And The Future Of Psychedelics For Mental Health

Atai Life Sciences N.V. to Report Q1, 2022 Results on May 16, 2022

Atai Life Sciences N.V., Annual General Meeting, May 25, 2022

We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely

atai Life Sciences N.V. Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments

Atai Life Sciences Announces Fda Investigational New Drug Clearance for Pcn-101 R-Ketamine Program

atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial of RL-007 in Cognitive Impairment Associated with Schizophrenia

Atai Life Sciences N.V. Announces the Launch of TryptageniX

決済の安定と成長

配当利回り対市場

株主への利益配当

株主配当金

高配当企業の発掘

配当金基準チェック /06